Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd. has demonstrated robust growth indicators, with remaining performance obligations increasing by approximately 43% year-over-year to around $70 million, signaling strong demand for its Deep TMS systems. The company shipped 95 Deep TMS systems in the fourth quarter of 2025, marking a 27% year-over-year increase, which supports a modestly raised revenue forecast for 2026 from $65.6 million to $66.8 million, alongside a new revenue estimate of $81.2 million for 2027. Additionally, the recent FDA approval of the Neurolief Proliv™Rx device enhances the company's market positioning and intrinsic value, contributing to an overall positive outlook driven by sustained operational performance and growth prospects in the neurostimulation market.

Bears say

The negative outlook on BrainsWay's stock is primarily attributed to the risks associated with the slower-than-anticipated uptake of its Deep TMS systems, which could hinder revenue growth. Additionally, the company's challenges in expanding reimbursement and market access, together with the potential inability to advance into new therapeutic indications, further contribute to concerns about its long-term financial viability. Lastly, the possibility of long-term dilution adds another layer of risk for investors, impacting their confidence in the stock's performance.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.